Skip to page content
Back to overview

Jun 25, 2019

Urinary marker for bladder cancer detection

Life Sciences, Diagnostics/Biomarker

  • The focal adhesion protein LASP-1 is a novel and simply detectable marker for urothelial carcinoma of the bladder (UCB)
  • LASP-1 overcomes the limitation of currently used cystoscopy and urine cytology for diagnosis of UCB
  • LASP-1 is detected in voided urine sediment of bladder cancer patients and is combinable with a second marker to further raise specificity/sensitivity

Your contact

Dr. Katrin Bercht

+49 (0) 89 5480177 - 16
Reference Number:


Urothelial carcinoma of the bladder (UCB) is the most common genitourinary cancer. ­Diagnosis of UCB currently relies on cystoscopy and urine cytology. Both examination methods have limitations. Urethrocystoscopy is expensive, invasive, and associated with ­postcystoscopy pain and/or risk of urinary infection. Cystoscopy has tendency to miss flat lesions, such as ­carcinoma in situ, while urine cytology is prone to missing ­well-differentiated low-grad ­lesions. After transurethral resection and adjuvant chemo- or immunotherapy, ­patients ­require regular follow-up cystoscopies due to the high recurrence rate, making TCC the most ­socioeconomically expensive tumor entity.


The LIM and SH3 (LASP)-1 protein is a focal adhesion protein involved in numerous ­biological and pathological processes and has been linked to the oncogenesis of bladder cancer. The protein is detected in voided urine sediment of bladder cancer patients and is described as a promising new marker for bladder cancer that overcomes the limitations of the current ­diagnostic tests for UCB.

Commercial Opportunities

  • Convenient marker for detection and especially follow-up examination of UCB simply detectable in spontaneously voided urine
  • Combinable with a second marker to further raise specificity/sensitivity

Development Status

In a cohort of 246 patients

  • the diagnostic accuracy of LASP1 detection was confirmed,
  • cut-off values were determined to handle erythrocyte/leukocyte
  • contamination (although in follow up studies hematuria isn’t a major issue),
  • a stabilization protocol for sample shipment was established


  • Reference 1

    Ardelt et al., Urol Oncol. 2013; 31(8): 1591-1598

  • Reference 2

    Butt et al., Biomark.Med. 2017; 11(4): 347-357

Interested? Get in touch!

Contact a specific team member via the Team section or simply use our contact form for your request.

Privacy settings

This website uses cookies. Cookies improve its usage and help make this website better.
Privacy Policy